NasdaqGM:VCYT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Veracyte's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VCYT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.0%

VCYT

4.0%

US Biotechs

3.9%

US Market


1 Year Return

42.0%

VCYT

39.5%

US Biotechs

18.5%

US Market

Return vs Industry: VCYT exceeded the US Biotechs industry which returned 39.7% over the past year.

Return vs Market: VCYT exceeded the US Market which returned 17.2% over the past year.


Shareholder returns

VCYTIndustryMarket
7 Day8.0%4.0%3.9%
30 Day-4.6%1.5%-4.3%
90 Day17.3%-3.0%8.1%
1 Year42.0%42.0%42.0%39.5%21.2%18.5%
3 Year252.0%252.0%15.3%9.7%38.2%29.0%
5 Year407.7%407.7%23.5%14.6%84.3%63.4%

Price Volatility Vs. Market

How volatile is Veracyte's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Veracyte undervalued compared to its fair value and its price relative to the market?

7.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VCYT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VCYT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VCYT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: VCYT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VCYT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VCYT is overvalued based on its PB Ratio (7.2x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Veracyte forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

49.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VCYT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VCYT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VCYT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VCYT's revenue (21.9% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: VCYT's revenue (21.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VCYT is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Veracyte performed over the past 5 years?

14.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VCYT is currently unprofitable.

Growing Profit Margin: VCYT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VCYT is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare VCYT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VCYT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: VCYT has a negative Return on Equity (-13.68%), as it is currently unprofitable.


Next Steps

Financial Health

How is Veracyte's financial position?


Financial Position Analysis

Short Term Liabilities: VCYT's short term assets ($172.7M) exceed its short term liabilities ($13.1M).

Long Term Liabilities: VCYT's short term assets ($172.7M) exceed its long term liabilities ($17.5M).


Debt to Equity History and Analysis

Debt Level: VCYT's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: VCYT's debt to equity ratio has reduced from 7.7% to 0.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VCYT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: VCYT has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 17.5% each year


Next Steps

Dividend

What is Veracyte current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VCYT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VCYT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VCYT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VCYT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VCYT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Bonnie Anderson (62 yo)

12.58yrs

Tenure

US$4,161,963

Compensation

Ms. Bonnie H. Anderson co-founded Veracyte, Inc. in 2008 and has served as its Chief Executive Officer and a Member of Board of Directors since February 2008. Ms. Anderson is Chairman of the Board at Verac ...


CEO Compensation Analysis

Compensation vs Market: Bonnie's total compensation ($USD4.16M) is about average for companies of similar size in the US market ($USD4.57M).

Compensation vs Earnings: Bonnie's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Bonnie Anderson
Co-Founder12.58yrsUS$4.16m0.40%
$ 7.3m
Keith Kennedy
CFO & COO3.75yrsUS$2.77m0.10%
$ 1.9m
Giulia Kennedy
Chief Scientific & Medical Officer12yrsUS$2.12m0.0019%
$ 34.7k
John Hanna
Chief Commercial Officer3.58yrsUS$2.03m0.039%
$ 721.7k
Mark Ho
Principal Accounting Officer1.17yrsno data0.033%
$ 608.7k
Ashish Kheterpal
Chief Information Officer3.5yrsno datano data
Tracy Morris
Vice President of Corporate Communications & Investor Relations0.42yrno datano data
James Erlinger
Executive VP0.17yrno datano data
Jessica Meng
Vice President of Marketing2.67yrsno datano data
Alfred Bowie
Vice President of Corporate & Business Development1.42yrsno datano data
Richard Kloos
Senior Medical Director of Endocrinology8.42yrsno datano data
Napoleon Cheng
Assistant Controller4.92yrsno datano data

3.5yrs

Average Tenure

55.5yo

Average Age

Experienced Management: VCYT's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Bonnie Anderson
Co-Founder12.58yrsUS$4.16m0.40%
$ 7.3m
Karin Eastham
Independent Director7.75yrsUS$196.04k0.023%
$ 429.8k
Fred Cohen
Independent Director13.67yrsUS$185.04k0%
$ 0
Evan Jones
Independent Director12.58yrsUS$185.04k0.044%
$ 812.2k
John Bishop
Lead Independent Director3.75yrsUS$209.04k0%
$ 0
Tina Nova Bennett
Independent Director4.83yrsUS$186.80k0%
$ 0
Kevin Gordon
Independent Director3.75yrsUS$194.04k0%
$ 0
Robert Epstein
Independent Director5.67yrsUS$189.04k0%
$ 0
Jens Holstein
Director0.17yrno datano data
Edison Liu
Member of Scientific Advisory Boardno datano datano data
Paul Ladenson
Member of Clinical Advisory Boardno datano datano data
Steven Sherman
Member of Clinical Advisory Boardno datano datano data

4.8yrs

Average Tenure

64yo

Average Age

Experienced Board: VCYT's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.8%.


Top Shareholders

Company Information

Veracyte, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Veracyte, Inc.
  • Ticker: VCYT
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.838b
  • Shares outstanding: 56.58m
  • Website: https://www.veracyte.com

Number of Employees


Location

  • Veracyte, Inc.
  • 6000 Shoreline Court
  • Suite 300
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VCYTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2013
12VDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2013

Biography

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify pa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/01 00:41
End of Day Share Price2020/09/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.